Pacira BioSciences' Q2 revenue misses estimates

Pacira Biosciences

05/08/2025 21:08

Overview

Pacira Q2 2025 revenue of $181.1 mln missed analyst expectations, per LSEG data

Adjusted EPS for Q2 2025 beats consensus, indicating strong operational performance

Company repurchased 2 mln shares, costing $50 mln, showing confidence in strategy

Outlook

Pacira narrows 2025 revenue guidance to $730 mln-$750 mln

Company raises 2025 non-GAAP gross margin forecast to 78-80%

Pacira reiterates 2025 non-GAAP R&D expense at $90 mln-$105 mln

Company sees 2025 non-GAAP SG&A expense at $290 mln-$320 mln

Result Drivers

ZILRETTA EXPANSION - Strategic collaboration with Johnson & Johnson MedTech to expand ZILRETTA's market reach

MANUFACTURING EFFICIENCIES - Large-scale EXPAREL manufacturing process improves gross margins and inventory management

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Miss
$181.10 mln
$183 mln (6 Analysts)
Q2 Adjusted EPS
Beat
$0.74
$0.71 (6 Analysts)
Q2 Adjusted Net Income
Beat
$36 mln
$34.70 mln (6 Analysts)
Q2 Net Income
-$4.80 mln
Q2 Adjusted EBITDA
Beat
$54.30 mln
$51.70 mln (5 Analysts)
Q2 Cash & Investments
$445.90 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 2 "hold" and 1 "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Pacira Biosciences Inc is $30.00, about 23.5% above its August 4 closing price of $22.94

The stock recently traded at 7 times the next 12-month earnings vs. a P/E of 9 three months ago

Press Release: ID:nGNX9n8pJv

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)